Novo Nordisk Gains Positive CHMP Opinion for FREHEMGO
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BAGSVAERD, Denmark — September 17, 2026 Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP)...
BALLERUP, Denmark — September 18, 2026 LEO Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for...
Irvine, California, USA — July 27, 2026 July 27, 2026 – AnHorn Medicines has announced the successful first subject...
BOSTON – July 24, 2026 Zevra Therapeutics, Inc. has announced that the European Medicines Agency’s (EMA) Committee for Medicinal...
HERZLIYA, Israel, July 15, 2026 Regentis Biomaterials announced that it has received approval from the European Notified Body for...
NORTH CHICAGO, Ill., June 23, 2026 AbbVie announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir) for the treatment...
